Neoplasm Grading

• 

  Subject Areas on Research

  • 111-In-capromab pendetide imaging using hybrid-γ camera-computer tomography technology is not reliable in detecting seminal vesicle invasion in patients with prostate cancer. 
  • A Multi-Institutional Prospective Trial Confirms Noninvasive Blood Test Maintains Predictive Value in African American Men. 
  • A Review and Update on Papillary Immature Metaplasia of the Uterine Cervix: A Distinct Subset of Low-Grade Squamous Intraepithelial Lesion, Proposing a Possible Cell of Origin. 
  • A multi-center population-based case-control study of ovarian cancer in African-American women: the African American Cancer Epidemiology Study (AACES). 
  • A multi-institutional experience of repeat regional chemotherapy for recurrent melanoma of extremities. 
  • A phase 2 multimodality trial of docetaxel/prednisone with sunitinib followed by salvage radiation therapy in men with PSA recurrent prostate cancer after radical prostatectomy. 
  • A phase I trial of the MEK inhibitor selumetinib (AZD6244) in pediatric patients with recurrent or refractory low-grade glioma: a Pediatric Brain Tumor Consortium (PBTC) study. 
  • A phase I trial of the farnesyl transferase inhibitor, SCH 66336, with temozolomide for patients with malignant glioma. 
  • A phase II single-arm study of irinotecan in combination with temozolomide (TEMIRI) in children with newly diagnosed high grade glioma: a joint ITCC and SIOPE-brain tumour study. 
  • A population-based comparison of adenocarcinoma of the large and small intestine: insights into a rare disease. 
  • A pretreatment nomogram for prediction of biochemical failure after primary cryoablation of the prostate. 
  • A signature of epithelial-mesenchymal plasticity and stromal activation in primary tumor modulates late recurrence in breast cancer independent of disease subtype. 
  • ABCA transporter gene expression and poor outcome in epithelial ovarian cancer. 
  • ACR Appropriateness Criteria® Post-treatment Follow-up Prostate Cancer. 
  • ACR appropriateness criteria post-treatment follow-up of renal cell carcinoma. 
  • Activation of Notch1 synergizes with multiple pathways in promoting castration-resistant prostate cancer. 
  • Active surveillance for prostate cancer: can we modernize contemporary protocols to improve patient selection and outcomes in the focal therapy era? 
  • Actual 10-Year Survivors After Resection of Hepatocellular Carcinoma. 
  • Adjuvant radiotherapy in the treatment of invasive intraductal papillary mucinous neoplasm of the pancreas: an analysis of the surveillance, epidemiology, and end results registry. 
  • Adult high-grade B-cell lymphoma with Burkitt lymphoma signature: genomic features and potential therapeutic targets. 
  • Adult infiltrating gliomas with WHO 2016 integrated diagnosis: additional prognostic roles of ATRX and TERT. 
  • African American Men With Low-Risk Prostate Cancer Are Candidates for Active Surveillance: The Will-Rogers Effect? 
  • African-American men with low-grade prostate cancer have higher tumor burdens: results from the Duke Prostate Center. 
  • Age-specific genome-wide association study in glioblastoma identifies increased proportion of 'lower grade glioma'-like features associated with younger age. 
  • Alcohol intake increases high-grade prostate cancer risk among men taking dutasteride in the REDUCE trial. 
  • Algorithms for prediction of the Oncotype DX recurrence score using clinicopathologic data: a review and comparison using an independent dataset. 
  • An update on noninvasive follicular thyroid neoplasm with papillary-like nuclear features. 
  • Analysis of perioperative radiation therapy in the surgical treatment of primary and recurrent retroperitoneal sarcoma. 
  • Anatomic tumor location influences the success of contemporary limb-sparing surgery and radiation among adults with soft tissue sarcomas of the extremities. 
  • Apparent Diffusion Coefficient Values of the Benign Central Zone of the Prostate: Comparison With Low- and High-Grade Prostate Cancer. 
  • Assessing clinically significant prostate cancer: Diagnostic properties of multiparametric magnetic resonance imaging compared to three-dimensional transperineal template mapping histopathology. 
  • Assessment of intra-observer variability in measurement of high-grade brain tumors. 
  • Assessment of multimodality therapy use for extremity sarcoma in the United States. 
  • Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer. 
  • Association between percentage of tumor involvement and Gleason score upgrading in low-risk prostate cancer. 
  • Association between preoperative erectile dysfunction and prostate cancer features--an analysis from the Duke Prostate Center Database. 
  • Autoantibodies against the cell surface-associated chaperone GRP78 stimulate tumor growth via tissue factor. 
  • Bevacizumab for the treatment of high-grade glioma. 
  • Biologic determinants of tumor recurrence in stage II colon cancer: validation study of the 12-gene recurrence score in cancer and leukemia group B (CALGB) 9581. 
  • Breast cancer screening, area deprivation, and later-stage breast cancer in Appalachia: does geography matter? 
  • Building a high-resolution T2-weighted MR-based probabilistic model of tumor occurrence in the prostate. 
  • Cabozantinib in genitourinary malignancies. 
  • Can proliferation biomarkers reliably predict recurrence in World Health Organization 2003 defined endometrial stromal sarcoma, low grade? 
  • Carcinoma of the ampulla of Vater: patterns of failure following resection and benefit of chemoradiotherapy. 
  • Cellular Blue Nevomelanocytic Lesions: Analysis of Clinical, Histological, and Outcome Data in 37 Cases. 
  • Cerebrovascular reactivity mapping in patients with low grade gliomas undergoing presurgical sensorimotor mapping with BOLD fMRI. 
  • Chemotherapy-related amenorrhea after adjuvant paclitaxel-trastuzumab (APT trial). 
  • Circulating Tumor Cells in Biochemical Recurrence of Prostate Cancer. 
  • Clinical, molecular, and genetic correlates of lymphatic spread in clear cell renal cell carcinoma. 
  • Comparison Between Adjuvant and Early-Salvage Postprostatectomy Radiotherapy for Prostate Cancer With Adverse Pathological Features. 
  • Comprehensive Surgical Treatment as the Mainstay of Management in Retroperitoneal Sarcomas: Retrospective Study from Two Non-sarcoma Specialist Centers. 
  • Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. 
  • Concordant, non-atypical breast papillomas do not require surgical excision: A 10-year multi-institution study and review of the literature. 
  • Cost Implications of an Evidence-Based Approach to Radiation Treatment After Lumpectomy for Early-Stage Breast Cancer. 
  • Cost analysis of colposcopy for abnormal cytology in post-treatment surveillance for cervical cancer. 
  • Cost comparison of radiation treatment options after lumpectomy for breast cancer. 
  • Cost-effectiveness of BRCA1 and BRCA2 mutation testing to target PARP inhibitor use in platinum-sensitive recurrent ovarian cancer. 
  • Cullin-1 and -2 Protein Expression in Colorectal Cancer: Correlation with Clinicopathological Variables. 
  • DNA methylation of imprinted gene control regions in the regression of low-grade cervical lesions. 
  • Description of selected characteristics of familial glioma patients - results from the Gliogene Consortium. 
  • Design of the North Carolina Prostate Cancer Comparative Effectiveness and Survivorship Study (NC ProCESS). 
  • Detection of prostate cancer with multiparametric MRI (mpMRI): effect of dedicated reader education on accuracy and confidence of index and anterior cancer diagnosis. 
  • Development and clinical validation of a real-time PCR assay for PITX2 DNA methylation to predict prostate-specific antigen recurrence in prostate cancer patients following radical prostatectomy. 
  • Diabetes and prostate cancer risk in the REDUCE trial. 
  • Differentially Expressed miRNAs in Hepatocellular Carcinoma Target Genes in the Genetic Information Processing and Metabolism Pathways. 
  • Discrete improvement in racial disparity in survival among patients with stage IV colorectal cancer: a 21-year population-based analysis. 
  • Distinctions in Breast Tumor Recurrence Patterns Post-Therapy among Racially Distinct Populations. 
  • Do all men with pathological Gleason score 8-10 prostate cancer have poor outcomes? Results from the SEARCH database. 
  • Does Any Racial Disparity Exist in Oncologic Outcomes After Primary Cryotherapy for Prostate Cancer? A Matched-pair Comparative Analysis of the Cryo On-Line Data Registry. 
  • Does adjuvant chemotherapy improve survival for women with early-stage uterine leiomyosarcoma? 
  • Does body mass index have an impact on the rate and location of positive surgical margins following robot assisted radical prostatectomy? 
  • Does mpMRI improve clinical criteria in selecting men with prostate cancer for active surveillance? 
  • Dual Somatostatin Receptor/FDG PET/CT Imaging in Metastatic Neuroendocrine Tumours: Proposal for a Novel Grading Scheme with Prognostic Significance. 
  • ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)†. 
  • Effects of Cancer Stage and Treatment Differences on Racial Disparities in Survival From Colon Cancer: A United States Population-Based Study. 
  • Efficacy of bevacizumab plus irinotecan in children with recurrent low-grade gliomas--a Pediatric Brain Tumor Consortium study. 
  • Efficiency of colorectal cancer care among veterans: analysis of treatment wait times at Veterans Affairs Medical Centers. 
  • Evaluation of Adjuvant Radiation Therapy for Resected Gallbladder Carcinoma: A Multi-institutional Experience. 
  • Evaluation of a breast cancer nomogram for predicting risk of ipsilateral breast tumor recurrences in patients with ductal carcinoma in situ after local excision. 
  • Evidence of a genetic link between endometriosis and ovarian cancer. 
  • Evolving management of low grade glioma: No consensus amongst treating clinicians. 
  • Examination of national lymph node evaluation practices for adult extremity soft tissue sarcoma. 
  • Expression of integrin α3β1 and cyclooxygenase-2 (COX2) are positively correlated in human breast cancer. 
  • FOXP3-positive regulatory T lymphocytes and epithelial FOXP3 expression in synchronous normal, ductal carcinoma in situ, and invasive cancer of the breast. 
  • Familial gliomas: cases in two pairs of brothers. 
  • Fibrosarcoma-like lipomatous neoplasm: a reappraisal of so-called spindle cell liposarcoma defining a unique lipomatous tumor unrelated to other liposarcomas. 
  • Five-Year Biochemical Progression-Free Survival Following Salvage Whole-Gland Prostate Cryoablation: Defining Success with Nadir Prostate-Specific Antigen. 
  • Foamy gland adenocarcinoma of the prostate: incidence, Gleason grade, and early clinical outcome. 
  • Focal Therapy Eligibility Determined by Magnetic Resonance Imaging/Ultrasound Fusion Biopsy. 
  • Frequency of "incidental" serous tubal intraepithelial carcinoma (STIC) in women without a history of or genetic risk factor for high-grade serous carcinoma: A six-year study. 
  • Frequency of breast cancer subtypes among African American women in the AMBER consortium. 
  • Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas. 
  • Gene set analysis of survival following ovarian cancer implicates macrolide binding and intracellular signaling genes. 
  • Genetic variants in ERCC1 and XPC predict survival outcome of non-small cell lung cancer patients treated with platinum-based therapy. 
  • Genetic variants in telomerase-related genes are associated with an older age at diagnosis in glioma patients: evidence for distinct pathways of gliomagenesis. 
  • Genetic variants in the TEP1 gene are associated with prostate cancer risk and recurrence. 
  • Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO. 
  • Genomic analysis of the origins and evolution of multicentric diffuse lower-grade gliomas. 
  • Germline Mutations in ATM and BRCA1/2 Distinguish Risk for Lethal and Indolent Prostate Cancer and are Associated with Early Age at Death. 
  • Gleason Grading, Biochemical Failure, and Prostate Cancer-Specific Death. 
  • Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors. 
  • Glioma-related seizures in relation to histopathological subtypes: a report from the glioma international case-control study. 
  • Grading of well-differentiated pancreatic neuroendocrine tumors is improved by the inclusion of both Ki67 proliferative index and mitotic rate. 
  • HOXB13 G84E-related familial prostate cancers: a clinical, histologic, and molecular survey. 
  • High-fructose corn syrup enhances intestinal tumor growth in mice. 
  • Histologic grade as prognostic indicator for mucoepidermoid carcinoma: a population-level analysis of 2400 patients. 
  • Histologic grading of the extent of residual carcinoma following neoadjuvant chemoradiation in pancreatic ductal adenocarcinoma: a predictor for patient outcome. 
  • Histologically benign, clinically aggressive: Progressive non-optic pathway pilocytic astrocytomas in adults with NF1. 
  • Histotype classification of ovarian carcinoma: A comparison of approaches. 
  • Hormone naïve prostate cancer: predicting and maximizing response intervals. 
  • Hypertension, obesity and prostate cancer biochemical recurrence after radical prostatectomy. 
  • Identification and Functional Validation of Reciprocal microRNA-mRNA Pairings in African American Prostate Cancer Disparities. 
  • Impact of Therapy on Genomics and Transcriptomics in High-Risk Prostate Cancer Treated with Neoadjuvant Docetaxel and Androgen Deprivation Therapy. 
  • Impact of health-related quality of life and fatigue on survival of recurrent high-grade glioma patients. 
  • Impact of pretransplantation conditioning regimens on outcomes of allogeneic transplantation for chemotherapy-unresponsive diffuse large B cell lymphoma and grade III follicular lymphoma. 
  • Impact of primary Gleason grade on risk stratification for Gleason score 7 prostate cancers. 
  • Improved grading of IDH-mutated astrocytic gliomas. 
  • Improved survival in the largest national cohort of adults with cerebellar versus supratentorial low-grade astrocytomas. 
  • Induction of the unfolded protein response drives enhanced metabolism and chemoresistance in glioma cells. 
  • Influence of molecular classification in anaplastic glioma for determining outcome and future approach to management. 
  • Inherited variant on chromosome 11q23 increases susceptibility to IDH-mutated but not IDH-normal gliomas regardless of grade or histology. 
  • Intended single-modality management of T1 and T2 tonsillar carcinomas: retrospective comparison of radical tonsillectomy vs radiation from a single institution. 
  • Interobserver Reproducibility of the PI-RADS Version 2 Lexicon: A Multicenter Study of Six Experienced Prostate Radiologists. 
  • Intra-tumor molecular heterogeneity in breast cancer: definitions of measures and association with distant recurrence-free survival. 
  • Intravesical rAd-IFNα/Syn3 for Patients With High-Grade, Bacillus Calmette-Guerin-Refractory or Relapsed Non-Muscle-Invasive Bladder Cancer: A Phase II Randomized Study. 
  • Invasion Patterns of Metastatic Extrauterine High-grade Serous Carcinoma With BRCA Germline Mutation and Correlation With Clinical Outcomes. 
  • Invasion patterns of metastatic high-grade serous carcinoma of ovary or fallopian tube associated with BRCA deficiency. 
  • Is clinical stage T2c prostate cancer an intermediate- or high-risk disease? 
  • Large-scale evaluation of common variation in regulatory T cell-related genes and ovarian cancer outcome. 
  • Long-term oncological outcomes of men undergoing radical prostatectomy with preoperative prostate-specific antigen <2.5 ng/ml and 2.5-4 ng/ml. 
  • Long-term results of an RTOG Phase II trial (00-19) of external-beam radiation therapy combined with permanent source brachytherapy for intermediate-risk clinically localized adenocarcinoma of the prostate. 
  • Longitudinal monitoring of EGFR mutations in plasma predicts outcomes of NSCLC patients treated with EGFR TKIs: Korean Lung Cancer Consortium (KLCC-12-02). 
  • Low levels of Stat5a protein in breast cancer are associated with tumor progression and unfavorable clinical outcomes. 
  • Low-risk and very-low-risk prostate cancer: is there a role for focal therapy in the era of active surveillance? Yes, the two approaches complement each other. 
  • Lowering positive margin rates at radical prostatectomy by color coding of biopsy specimens to permit individualized preservation of the neurovascular bundles: is it feasible? a pilot investigation. 
  • Magnetic resonance imaging as a predictor of pathologic response in patients treated with neoadjuvant systemic treatment for operable breast cancer. Translational Breast Cancer Research Consortium trial 017. 
  • Managing intracranial incidental findings suggestive of low-grade glioma: learning from experience. 
  • Metabolic syndrome-like components and prostate cancer risk: results from the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) study. 
  • Metformin does not affect risk of biochemical recurrence following radical prostatectomy: results from the SEARCH database. 
  • Metformin use and risk of prostate cancer: results from the REDUCE study. 
  • Minimally invasive surgery versus laparotomy in women with high grade endometrial cancer: a multi-site study performed at high volume cancer centers. 
  • Molecular Profiling to Determine Clonality of Serial Magnetic Resonance Imaging/Ultrasound Fusion Biopsies from Men on Active Surveillance for Low-Risk Prostate Cancer. 
  • Molecular Signature to Risk-Stratify Prostate Cancer of Intermediate Risk. 
  • Morphologic correlates of molecular alterations in extrauterine Müllerian carcinomas. 
  • Morphologic patterns associated with BRCA1 and BRCA2 genotype in ovarian carcinoma. 
  • Morphological and molecular features of astroblastoma, including BRAFV600E mutations, suggest an ontological relationship to other cortical-based gliomas of children and young adults. 
  • Most Gleason 8 Biopsies are Downgraded at Prostatectomy-Does 4 + 4 = 7? 
  • Multiregional Radiogenomic Assessment of Prostate Microenvironments with Multiparametric MR Imaging and DNA Whole-Exome Sequencing of Prostate Glands with Adenocarcinoma. 
  • Mutational landscape and clonal architecture in grade II and III gliomas. 
  • Mutations in IDH1, IDH2, and in the TERT promoter define clinically distinct subgroups of adult malignant gliomas. 
  • NCCN Guidelines Insights: Central Nervous System Cancers, Version 1.2017. 
  • Neoadjuvant Systemic Therapy for Breast Cancer: Factors Influencing Surgeons' Referrals. 
  • New prostate cancer prognostic grade group (PGG): Can multiparametric MRI (mpMRI) accurately separate patients with low-, intermediate-, and high-grade cancer? 
  • Novel roles of apoptotic caspases in tumor repopulation, epigenetic reprogramming, carcinogenesis, and beyond. 
  • Nuclear grade and necrosis predict prognosis in malignant epithelioid pleural mesothelioma: a multi-institutional study. 
  • O6-Methylguanine DNA Methyltransferase Status Does Not Predict Response or Resistance to Alkylating Agents in Well-Differentiated Pancreatic Neuroendocrine Tumors. 
  • Obesity and risk of ovarian cancer subtypes: evidence from the Ovarian Cancer Association Consortium. 
  • Obesity is associated with worse overall survival in women with low-grade papillary serous epithelial ovarian cancer. 
  • Obesity, weight gain, and ovarian cancer risk in African American women. 
  • Open surgical partial nephrectomy for upper tract urothelial carcinoma. 
  • Open versus laparoscopic portal lymphadenectomy in gallbladder cancer: is there a difference in lymph node yield? 
  • Ototoxicity in children with high-risk neuroblastoma: prevalence, risk factors, and concordance of grading scales--a report from the Children's Oncology Group. 
  • Outcome after bevacizumab clinical trial therapy among recurrent grade III malignant glioma patients. 
  • Outcomes of primary surgical cytoreduction in patients with BRCA-associated high-grade serous ovarian carcinoma. 
  • Over half of contemporary clinical Gleason 8 on prostate biopsy are downgraded at radical prostatectomy. 
  • Pathologic Complete Response After Neoadjuvant Chemotherapy and Long-Term Outcomes Among Young Women With Breast Cancer. 
  • Pathologic grade and tumor size are associated with recurrence-free survival in patients with duodenal neuroendocrine tumors. 
  • Pathological upgrading at radical prostatectomy for patients with Grade Group 1 prostate cancer: implications of confirmatory testing for patients considering active surveillance. 
  • Periprostatic Fat: A Risk Factor for Prostate Cancer? 
  • Phase 1 dose escalation trial of the safety and pharmacokinetics of cabozantinib concurrent with temozolomide and radiotherapy or temozolomide after radiotherapy in newly diagnosed patients with high-grade gliomas. 
  • Phase 2 Study of the Safety and Antitumor Activity of Apalutamide (ARN-509), a Potent Androgen Receptor Antagonist, in the High-risk Nonmetastatic Castration-resistant Prostate Cancer Cohort. 
  • Phase I/II dose-escalation study of PI3K inhibitors pilaralisib or voxtalisib in combination with letrozole in patients with hormone-receptor-positive and HER2-negative metastatic breast cancer refractory to a non-steroidal aromatase inhibitor. 
  • Phase II study of Gleevec® plus hydroxyurea (HU) in adults with progressive or recurrent meningioma. 
  • Phase II study of cilengitide (EMD 121974, NSC 707544) in patients with non-metastatic castration resistant prostate cancer, NCI-6735. A study by the DOD/PCF prostate cancer clinical trials consortium. 
  • Phase II study of single-agent orteronel (TAK-700) in patients with nonmetastatic castration-resistant prostate cancer and rising prostate-specific antigen. 
  • Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma. 
  • Phase III trial of selenium to prevent prostate cancer in men with high-grade prostatic intraepithelial neoplasia: SWOG S9917. 
  • Physician Recommendations Trump Patient Preferences in Prostate Cancer Treatment Decisions. 
  • Positive surgical margins in radical prostatectomy patients do not predict long-term oncological outcomes: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) cohort. 
  • Predicting Residual Disease in Incidental Gallbladder Cancer: Risk Stratification for Modified Treatment Strategies. 
  • Predicting biopsy-proven prostate cancer recurrence following cryosurgery. 
  • Predicting bone scan positivity after biochemical recurrence following radical prostatectomy in both hormone-naive men and patients receiving androgen-deprivation therapy: results from the SEARCH database. 
  • Predicting bone scan positivity in non-metastatic castration-resistant prostate cancer. 
  • Predictors of Rectourethral Fistula Formation After Primary Whole-Gland Cryoablation for Prostate Cancer: Results from the Cryo On-Line Database Registry. 
  • Predictors of surveillance mammography outcomes in women with a personal history of breast cancer. 
  • Preoperative or postoperative radiotherapy versus surgery alone for retroperitoneal sarcoma: a case-control, propensity score-matched analysis of a nationwide clinical oncology database. 
  • Preoperative predictors of pathologic stage T2a and pathologic Gleason score ≤ 6 in men with clinical low-risk prostate cancer treated with radical prostatectomy: reference for active surveillance. 
  • Preoperative predictors of pathologic stage T2a in low-risk prostate cancer: implications for focal therapy. 
  • Preoperative weight change and risk of adverse outcome following radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital database. 
  • Presentation and management of gastrointestinal stromal tumors of the duodenum: a multi-institutional analysis. 
  • Primary Cryotherapy for High-Grade Clinically Localized Prostate Cancer: Oncologic and Functional Outcomes from the COLD Registry. 
  • Principles of T2 *-weighted dynamic susceptibility contrast MRI technique in brain tumor imaging. 
  • Profiling Hsp90 differential expression and the molecular effects of the Hsp90 inhibitor IPI-504 in high-grade glioma models. 
  • Prognostic marker analysis in pediatric intracranial ependymomas. 
  • Prognostic significance of differential expression of angiogenic genes in women with high-grade serous ovarian carcinoma. 
  • Prognostic utility of cell cycle progression score in men with prostate cancer after primary external beam radiation therapy. 
  • Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort. 
  • Propensity Score-Matched Comparison of Partial to Whole-Gland Cryotherapy for Intermediate-Risk Prostate Cancer: An Analysis of the Cryo On-Line Data Registry Data. 
  • Prostate Specific Antigen Nadir of 0.1 or Less Is a Predictor of Treatment Success in Men Undergoing Salvage Whole Prostate Gland Cryoablation. 
  • Prostate-specific antigen level, stage or Gleason score: which is best for predicting outcomes after radical prostatectomy, and does it vary by the outcome being measured? Results from Shared Equal Access Regional Cancer Hospital database. 
  • Quality of life after postmastectomy radiotherapy in patients with intermediate-risk breast cancer (SUPREMO): 2-year follow-up results of a randomised controlled trial. 
  • Race-specific molecular alterations correlate with differential outcomes for black and white endometrioid endometrial cancer patients. 
  • Radiogenomics of lower-grade glioma: algorithmically-assessed tumor shape is associated with tumor genomic subtypes and patient outcomes in a multi-institutional study with The Cancer Genome Atlas data. 
  • Rationale and study protocol for the Patient-Centered Outcome Aid (PCOA) randomized controlled trial: A personalized decision tool for newly diagnosed ovarian cancer patients. 
  • Re: Radical Prostatectomy, External Beam Radiotherapy, or External Beam Radiotherapy with Brachytherapy Boost and Disease Progression and Mortality in Patients with Gleason Score 9-10 Prostate Cancer. 
  • Recurrence and Survival After Resection of Small Intraductal Papillary Mucinous Neoplasm-associated Carcinomas (≤20-mm Invasive Component): A Multi-institutional Analysis. 
  • Rising PSA Level in an Anxious Postprostatectomy Patient. 
  • Risk Stratification Among Men With Prostate Imaging Reporting and Data System version 2 Category 3 Transition Zone Lesions: Is Biopsy Always Necessary? 
  • Role of 18 F-FDG PET/CT differentiating olfactory neuroblastoma from sinonasal undifferentiated carcinoma. 
  • Role of Increased n-acetylaspartate Levels in Cancer. 
  • Salvage Radiation Therapy Dose Response for Biochemical Failure of Prostate Cancer After Prostatectomy-A Multi-Institutional Observational Study. 
  • Sequence of hormonal therapy and radiotherapy field size in unfavourable, localised prostate cancer (NRG/RTOG 9413): long-term results of a randomised, phase 3 trial. 
  • Serum prostate-specific antigen (PSA) concentration is positively associated with rate of disease reclassification on subsequent active surveillance prostate biopsy in men with low PSA density. 
  • Serum testosterone and dihydrotestosterone and prostate cancer risk in the placebo arm of the Reduction by Dutasteride of Prostate Cancer Events trial. 
  • Should New "No Ink On Tumor" Lumpectomy Margin Guidelines be Applied to Ductal Carcinoma In Situ (DCIS)? A Retrospective Review Using Shaved Cavity Margins. 
  • Simpson Grade I-III Resection of Spinal Atypical (World Health Organization Grade II) Meningiomas is Associated With Symptom Resolution and Low Recurrence. 
  • Simulation Modeling of Cancer Clinical Trials: Application to Omitting Radiotherapy in Low-risk Breast Cancer. 
  • Smoking and risk of low- and high-grade prostate cancer: results from the REDUCE study. 
  • Statin use and the risk of recurrence after radical prostatectomy in a cohort of men with inherited and/or early-onset forms of prostate cancer. 
  • Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. 
  • Surgical staging for endometrial cancer in the elderly - is there a role for lymphadenectomy? 
  • Surgical treatment and prognosis in patients with high-grade soft tissue malignant fibrous histiocytoma of the extremities. 
  • Surveillance after prostate focal therapy. 
  • Survival and low-grade glioma: the emergence of genetic information. 
  • TERT promoter mutations contribute to IDH mutations in predicting differential responses to adjuvant therapies in WHO grade II and III diffuse gliomas. 
  • Targeted Biopsy to Detect Gleason Score Upgrading during Active Surveillance for Men with Low versus Intermediate Risk Prostate Cancer. 
  • The 2015 World Health Organization Classification of Tumors of the Pleura: Advances since the 2004 Classification. 
  • The dynamics of death in prostate cancer. 
  • The effect of the setting of a positive surgical margin in soft tissue sarcoma. 
  • The high-grade (WHO G3) pancreatic neuroendocrine tumor category is morphologically and biologically heterogenous and includes both well differentiated and poorly differentiated neoplasms. 
  • The impact of race and partner status on patterns of care and survival in young women with early-stage cervical cancer. 
  • The influence of diabetes severity on receipt of guideline-concordant treatment for breast cancer. 
  • The influence of radiation modality and lymph node dissection on survival in early-stage endometrial cancer. 
  • The use of adjuvant radiotherapy in elderly patients with early-stage breast cancer: changes in practice patterns after publication of Cancer and Leukemia Group B 9343. 
  • The use of fluorescein sodium in the biopsy and gross-total resection of a tectal plate glioma. 
  • The use of radiation therapy in localized high-grade soft tissue sarcoma and potential impact on survival. 
  • Transcript expression in endometrial cancers from Black and White patients. 
  • Treatment Response and Outcomes of Grade 3 Pancreatic Neuroendocrine Neoplasms Based on Morphology: Well Differentiated Versus Poorly Differentiated. 
  • Treatment modalities for T1N0 esophageal cancers: a comparative analysis of local therapy versus surgical resection. 
  • Treatment of extensive metastatic colorectal cancer to the liver with systemic and hepatic arterial infusion chemotherapy and two-stage hepatic resection: the role of salvage therapy for recurrent disease. 
  • Trends in Treatment Patterns and Outcomes for Ductal Carcinoma In Situ. 
  • Use of a novel sentinel lymph node mapping algorithm reduces the need for pelvic lymphadenectomy in low-grade endometrial cancer. 
  • Usual and unusual histologic patterns of high Gleason score 8 to 10 adenocarcinoma of the prostate in needle biopsy tissue. 
  • Uterine Sarcoma, Version 1.2016: Featured Updates to the NCCN Guidelines. 
  • Utilization of genomic signatures to identify high-efficacy candidate drugs for chemorefractory endometrial cancers. 
  • Validation of an RNA cell cycle progression score for predicting death from prostate cancer in a conservatively managed needle biopsy cohort. 
  • Validation of an oligo-gene signature for the prognostic stratification of ductal carcinoma in situ (DCIS). 
  • Validation of the 2015 prostate cancer grade groups for predicting long-term oncologic outcomes in a shared equal-access health system. 
  • Value of Tracking Biopsy in Men Undergoing Active Surveillance of Prostate Cancer. 
  • Variants near TERT and TERC influencing telomere length are associated with high-grade glioma risk. 
  • Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study. 
  • [Femur reconstruction using combined autologous fibula transfer and humeral allograft]. 
• 

  Keywords of People

  • Berchuck, Andrew, James M. Ingram Distinguished Professor of Gynecologic Oncology, Obstetrics and Gynecology, Gynecologic Oncology
  • Koontz, Bridget Fey, Associate Professor of Radiation Oncology, Radiation Oncology
  • McLendon, Roger Edwin, Professor of Pathology, Pathology
  • Moorman, Patricia Gripka, Professor in Family Medicine and Community Health, Duke Cancer Institute
  • Preminger, Glenn Michael, James F. Glenn, M.D. Distinguished Professor of Urology, Surgery
  • Roy Choudhury, Kingshuk, Adjunct Associate Professor in the Department of Biostatistics and Bioinformatics, Biostatistics & Bioinformatics
  • Sampson, John Howard, Robert H., M.D. and Gloria Wilkins Professor of Neurosurgery, in the School of Medicine, Immunology
  • Yan, Hai, Henry S. Friedman Distinguished Professor of Neuro-Oncology in the School of Medicine, Pathology
  • Zafar, Syed Yousuf, Associate Professor of Medicine, Medicine, Medical Oncology